Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line chemot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Tani, Nozomi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471014/
https://ncbi.nlm.nih.gov/pubmed/32706170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados